Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention

Platelets

Volumn 22, Issue 4, 2011, Pages 305-307

  Ahn, Sung Gyun ^a   Lee, Seung Hwan ^a   Sung, Joong Kyung ^a   Kim, Jang Young ^a   Yoon, Junghan ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

clopidogrel; observer variation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AGED; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LETTER; MALE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VERYFINOW P2Y12 ASSAY;

AGED; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 79955995665     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.525268     Document Type: Letter

References (12)

1. Arméro S, Camoin Jau L, Aït Mokhtar O, Mancini J, Burignat- Bonello C, Tahirou I, Arques S, Dignat-George F, Paganelli F, Bonello L. Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 2010;21:503-507.
2. Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 2010;21:94-100.
3. van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. Platelets 2008;19:479-488.
4. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29:992-1000. (Pubitemid 351844676)
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913. (Pubitemid 36736631)
6. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
7. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396. (Pubitemid 40615608)
8. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet J-L, Alessi M-C. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549.
9. Vila PM, Zafar MU, Badimon JJ. Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. Platelets 2009;20:531-538.
10. Myles PS, Cui J. Using the Bland-Altman method to measure agreement with repeated measures. Br J Anaesth. 2007; 99:309-311. (Pubitemid 47316383)
11. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754-762.
12. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. Am Heart J. 2009; 157:818-824.e1.